Gene therapy tackles HIV and lymphoma in one shot
NCT ID NCT01961063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether giving gene therapy after standard chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds anti-HIV genes to the patient's own blood stem cells, aiming to help the body fight HIV. Only 3 participants were enrolled, and the main goal was to check for side effects and see if the modified cells survive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIDS-RELATED NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new strategy break the cycle of HIV care dropout?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Smart pill bottles and health coaches team up to tackle HIV in the deep south
- Can one Mega-Dose of an antifungal beat a deadly infection in AIDS patients?
- Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
- Immune-Boosting cocktail aims to free HIV patients from daily medication